1.373USD-1.94%Mkt Cap: 66.94M USDP/E: —Last update: 2026-05-26
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilas…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap66.94M USD
Enterprise Value40.27M USD
Revenue (TTM)596.64K USD
Gross Profit31.05K USD
Net Income (TTM)-12.00M USD
Revenue/Share0.0120 USD
Last Price1.373 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.19
PEG—
EV/EBITDA-3.12
EV/Revenue67.49
P/S113.02
P/B1.71
EPS (TTM)-0.23
EPS (Forward)-0.43
52W Range
1.17026% of range1.960
52W High1.960 USD
52W Low1.170 USD
Profitability
Gross Margin7.58%
Oper. Margin-1516.60%
EBITDA Margin0.00%
Profit Margin-2928.78%
ROE-28.85%
ROA-26.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.81M USD
CapEx (TTM)2.90K USD
FCF Margin-998.95%
FCF Yield-8.90%
Net Debt-27.16M USD
Net Debt/EBITDA2.11
Balance Sheet
Debt/Equity0.00
Current Ratio9.09
Quick Ratio8.91
Book Value/Sh0.8010 USD
Cash/Share0.5550 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)9.000 USD
Target Range6.000 USD – 11.00 USD
# Analysts4
Ownership
Shares Out.49.22M
Float42.26M
Insiders2.88%
Institutions11.04%
Short Interest
Short Ratio6.3d
Short % Float0.36%
Short % Out.0.35%
Shares Short172.33K
Short (prev mo.)201.03K
Technical
SMA 501.412 (-2.8%)
SMA 2001.409 (-2.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)20.92K
Avg Vol (10d)18.42K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—